Ali Mohammed, Mohamed Ahmed, Ahmed Hussam Elamin, Malviya Ajay, Atchia Ismael
Northumbria Healthcare NHS Foundation Trust , North Shields , United Kingdom.
Health Education North East , Newcastle , United Kingdom.
J Ultrason. 2018;18(75):332-337. doi: 10.15557/JoU.2018.0048.
This review aims to determine whether ultrasound-guided platelet-rich plasma injection has any role in improving clinical outcomes in patients with hip osteoarthritis. A search of the National Institute for Health and Care Excellence database using the Healthcare Databases Advanced Search tool was conducted. The PubMed database was also utilised to search the Medical Literature Analysis and Retrieval System Online, Excerpta Medica database, Cumulative Index of Nursing and Allied Health and Allied and Complimentary Medicine databases. The Preferred Reporting Items for Systematic Review and Meta-Analysis methodology guidance was employed and a quality assessment was performed using the Jadad score. Three randomised clinical trials met the inclusion criteria and were included for analysis. All three trials were of good quality based on the Jadad score. A total of 115 patients out of 254 received platelet-rich plasma injections under ultrasound guidance. The platelet-rich plasma recipient group included 61 males and 54 females with an age range from 53 to 71 years. Outcome scores show an improvement of symptoms and function maintained up to 12 months following platelet-rich plasma injection. Literature to date concludes that intra-articular platelet-rich plasma injections of the hip, performed under ultrasound guidance to treat hip osteoarthritis, are well tolerated and potentially efficacious in delivering long-term and clinically significant pain reduction and functional improvement in patients with hip osteoarthritis. Larger future trials including a placebo group are required to further evaluate these promising results. Level I, a systematic review of level I studies. This review aims to determine whether ultrasound-guided platelet-rich plasma injection has any role in improving clinical outcomes in patients with hip osteoarthritis. A search of the National Institute for Health and Care Excellence database using the Healthcare Databases Advanced Search tool was conducted. The PubMed database was also utilised to search the Medical Literature Analysis and Retrieval System Online, Excerpta Medica database, Cumulative Index of Nursing and Allied Health and Allied and Complimentary Medicine databases. The Preferred Reporting Items for Systematic Review and Meta-Analysis methodology guidance was employed and a quality assessment was performed using the Jadad score. Three randomised clinical trials met the inclusion criteria and were included for analysis. All three trials were of good quality based on the Jadad score. A total of 115 patients out of 254 received platelet-rich plasma injections under ultrasound guidance. The platelet-rich plasma recipient group included 61 males and 54 females with an age range from 53 to 71 years. Outcome scores show an improvement of symptoms and function maintained up to 12 months following platelet-rich plasma injection. Literature to date concludes that intra-articular platelet-rich plasma injections of the hip, performed under ultrasound guidance to treat hip osteoarthritis, are well tolerated and potentially efficacious in delivering long-term and clinically significant pain reduction and functional improvement in patients with hip osteoarthritis. Larger future trials including a placebo group are required to further evaluate these promising results. Level I, a systematic review of level I studies.
本综述旨在确定超声引导下富血小板血浆注射在改善髋骨关节炎患者临床结局方面是否有作用。使用医疗数据库高级搜索工具对英国国家卫生与临床优化研究所数据库进行了检索。还利用PubMed数据库检索了医学文献分析与联机检索系统、医学文摘数据库、护理及相关健康累积索引以及补充和替代医学数据库。采用系统评价和Meta分析的首选报告项目方法指南，并使用Jadad评分进行质量评估。三项随机临床试验符合纳入标准并纳入分析。根据Jadad评分，所有三项试验质量良好。254名患者中有115名在超声引导下接受了富血小板血浆注射。富血小板血浆接受组包括61名男性和54名女性，年龄范围为53至71岁。结果评分显示，富血小板血浆注射后症状和功能改善可持续长达12个月。迄今为止的文献得出结论，在超声引导下进行髋关节内富血小板血浆注射以治疗髋骨关节炎，耐受性良好，并且在减轻髋骨关节炎患者的长期临床显著疼痛和改善功能方面可能有效。未来需要开展包括安慰剂组的更大规模试验，以进一步评估这些有前景的结果。I级，I级研究的系统评价。本综述旨在确定超声引导下富血小板血浆注射在改善髋骨关节炎患者临床结局方面是否有作用。使用医疗数据库高级搜索工具对英国国家卫生与临床优化研究所数据库进行了检索。还利用PubMed数据库检索了医学文献分析与联机检索系统、医学文摘数据库、护理及相关健康累积索引以及补充和替代医学数据库。采用系统评价和Meta分析的首选报告项目方法指南，并使用Jadad评分进行质量评估。三项随机临床试验符合纳入标准并纳入分析。根据Jadad评分，所有三项试验质量良好。254名患者中有115名在超声引导下接受了富血小板血浆注射。富血小板血浆接受组包括61名男性和54名女性，年龄范围为53至71岁。结果评分显示，富血小板血浆注射后症状和功能改善可持续长达12个月。迄今为止的文献得出结论，在超声引导下进行髋关节内富血小板血浆注射以治疗髋骨关节炎，耐受性良好，并且在减轻髋骨关节炎患者的长期临床显著疼痛和改善功能方面可能有效。未来需要开展包括安慰剂组的更大规模试验，以进一步评估这些有前景的结果。I级，I级研究的系统评价。
